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Abstract: Orexin A, an endogenous peptide involved in several functions including reward, acts
via activation of orexin receptors OX1 and OX2, Gq-coupled GPCRs. We examined the effect of
a selective OX1 agonist, OXA (17-33) on cytosolic calcium concentration, [Ca2+]i, in neurons of
nucleus accumbens, an important area in the reward circuit. OXA (17-33) increased [Ca2+]i in a
dose-dependent manner; the effect was prevented by SB-334867, a selective OX1 receptors antagonist.
In Ca2+-free saline, the OXA (17-33)-induced increase in [Ca2+]i was not affected by pretreatment with
bafilomycin A1, an endo-lysosomal calcium disrupter, but was blocked by 2-APB and xestospongin
C, antagonists of inositol-1,4,5-trisphosphate (IP3) receptors. Pretreatment with VU0155056, PLD
inhibitor, or BD-1047 and NE-100, Sigma-1R antagonists, reduced the [Ca2+]i response elicited by
OXA (17-33). Cocaine potentiated the increase in [Ca2+]i by OXA (17-33); the potentiation was
abolished by Sigma-1R antagonists. Our results support an additional signaling mechanism for
orexin A-OX1 via choline-Sigma-1R and a critical role for Sigma-1R in the cocaine–orexin A interaction
in nucleus accumbens neurons.
Keywords: choline; orexin A; OX1 receptor; phospholipase D; PLD; reward
1. Introduction
Orexin A and B (also known as hypocretin-1 and -2) are endogenous neuropeptides
synthesized in hypothalamic neurons that control appetite, sleep/wakefulness, hormone
release, stress, and drug-seeking behavior [1–3]. Hypothalamic neurons expressing orexins
project to several brain areas such as ventral tegmental area, nucleus accumbens, dorsal
raphe nucleus, and locus coeruleus [2,4].
Orexins act via OX1 and OX2 receptors, Gq-coupled GPCRs that may signal also via
Gs or Gi proteins [5,6]. OX1 receptors have a preferential role in addiction, reward, and
motivation, while OX2 receptors are involved in arousal [3,7]. OX1 receptor activation
leads to an increase in cytosolic Ca2+ concentration, [Ca2+]i, subsequent to activation
of phospholipase C (PLC) and generation of inositol-1,4,5-trisphosphate (IP3) [6,8]. In
addition to the PLC coupling, activation of OX1 receptor leads to phospholipase D (PLD)
activation [9,10]. PLD-mediated hydrolysis of phosphatidylcholine produces choline and
phosphatidic acid [11]. Choline activates Sigma-1R [12], a chaperone protein residing at
the endoplasmic reticulum that potentiates IP3-induced Ca2+ release [13].
OX1 receptors were identified in brain nuclei from the reward circuit, including
nucleus accumbens [14,15], and OX1-selective antagonists have been evaluated as potential
therapeutic agents for addiction treatment [16–18]. Previous studies indicate that orexins
via OX1 receptor activation are involved in the response to cocaine and play multiple
roles in cocaine addiction-related behaviors [7,19–21]. Orexin-OX1 signaling is required
for stimulant locomotor sensitization and cocaine seeking when it is driven by highly
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motivated states [3]. OX1 receptors in the nucleus accumbens mediate chronic cocaine-
induced locomotor sensitization [22]. Other studies indicate that SB-334867, a selective
OX1 receptor antagonist, prevents cocaine seeking and is a potential treatment target for
cocaine relapse prevention [23].
Cocaine acts primarily by blocking the dopamine transporter, thus increasing dopamine
transmission in the nucleus accumbens [24], an important area in the reward circuit [25].
In addition, cocaine binds to and activates Sigma-1R [26]. Since nucleus accumbens neu-
rons express Sigma-1R [27–29] and OX1 receptors [14,15] and behavioral studies support the
cocaine–orexin interaction at this level [3,22], in this work, we examined the underlying mech-
anisms and role of Sigma-1R in the cocaine–orexin interaction in nucleus accumbens neurons.
2. Results
2.1. OXA (17-33) Increases Cytosolic Ca2+, [Ca2+]i, in Nucleus Accumbens Neurons via OX1
Receptor Activation
OXA (17-33) (0.1–100 nM), i.e., truncated orexin A, a selective OX1 agonist [1,30], increased
[Ca2+]i in nucleus accumbens neurons in a dose-dependent manner (Figure 1). OXA (17-33)
(10 nM) increased the fluorescence F340/380 ratio of Fura-2AM-loaded nucleus accumbens
neurons; the effect was prevented by pretreatment with SB-334867 (1 µM), a selective
OX1 antagonist [31] (Figure 1A). OXA (17-33) (10 nM) produced a transient increase in
[Ca2+]i that was abolished by SB-334867 (Figure 1B). Comparison of the amplitude of the
increase in [Ca2+]i produced by different concentrations of OXA (17-33) (0.1, 1, 10, 100 nM)
is illustrated in Figure 1C (n = 6 neurons/each concentration). Of note, 20–30 neurons were
tested for each condition, and an increase in [Ca2+]i was identified in about 25% of neurons
tested; the amplitude of [Ca2+]i from the response of six neurons was used for analysis.
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Figure 1. OXA (17-33) increases cytosolic Ca2+ concentration, [Ca2+]i, in nucleus accumbens neurons
via OX1 receptor activation. (A) Representative examples of fluorescence F340/380 ratio of Fura-2AM-
loaded nucleus accumbens neurons in basal conditions (left) and after treatment with OXA (17-33)
(10 nM), a selective OX1 agonist, alone (top right) or in the presence of OX1 antagonist, SB-334867
(1 µM) (bottom right). (B) OXA (17-33) (10 nM) produced a transient increase in [Ca2+]i; the effect was
abolished by SB-334867. (C) Comparison of the amplitude of [Ca2+]i increase (mean + SD) produced by
OXA (17–33) (0.1, 1, 10, and 100 nM); p < 0.05 as compared with the amplitude of [Ca2+]i increase produced
by each concentration (*) or by OXA (17-33) (10 nM) (**); n = 6 neurons/each concentration tested.
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2.2. OXA (17-33) Increases [Ca2+]i via IP3-Dependent Mechanism
In Ca2+-free saline, OXA (17-33) (10 nM) elicited an increase in [Ca2+]i of lower
amplitude (Figure 2) than in Ca2+-containing saline (Figure 1). The Ca2+ response to
OXA (17-33) (10 nM) in Ca2+-free saline was abolished by pretreatment with IP3 receptors
antagonists 2-aminoethoxydiphenyl borate (2-APB, 100 µM, 15 min) and xestospongin C
(10 µM, 15 min) [32], indicating a PLC-dependent mechanism. Disruption of lysosomal
Ca2+ stores with bafilomycin A1 (1 µM, 1 h preincubation), a V-type ATPase inhibitor that
prevents lysosomal acidification [33], did not affect the Ca2+ response to orexin (10 nM)
(Figure 2). OXA (17-33) (10 nM)-induced Ca2+ responses (average ± SD) in Ca2+-free saline
in nucleus accumbens neurons in the absence and presence of 2-APB and xestospongin C
or bafilomycin A1 are illustrated in Figure 2A, and a comparison of the amplitude of the
[Ca2+]i increase in each condition is illustrated in Figure 2B (n = 6 neurons/condition).
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induced in Ca2+-free saline by OXA (17-33) (10 nM) alone (left) and OXA (17-33) (10 nM) after pretreatment with 2-
aminoethoxydiphenyl borate (2- PB, 100 µM) and xestospongin C (XeC, 10 µM, 15 min), IP3 receptor ant gonis s (middle),
or with bafilomycin A1 (Baf, 1 µM) (right). (B) Compariso of the amplitude of the increase in [Ca2+]i (average + SD) in each
condition. Pretreatment with 2-APB and xestospongin C abolished the Ca2+ response induced by OXA (17-33). * p < 0.05;
n = 6 neurons/condition.
2.3. OXA (17-33) Increases [Ca2+]i via Choline-Sigma-1R-Dependent Mechanism
Pretreatment with VU0155056 (1 µM, 30 min), a PLD inhibitor [34], reduced the ampli-
tude of OXA (17-33) (10 nM)-induced increase in [C 2+]i by 33% (Figure 3). Pretr atm nt
with BD1047 (50 µM, 30 min) or NE-100 (5 µM, 30 min) (S gma-1R antagonists) [35,36] re-
duced the Ca2+ response to OXA (17-33) (10 nM) by 18.1% and 20.4%, respectively. Average
Ca2+ responses induced by OXA (17-33) alone and in the presence of PLD inhibitor and
Sigma-1R antagonists are illustrated in Figure 3A, and a comparison of the amplitude of
the [Ca2+]i increase in each condition is illustrated in Figure 3B (n = 6 neurons/condition).
2.4. Cocaine Potentiates OXA (17-33)-Induced Increase in [Ca2+]i via Sigma-1R Activation
Cocaine (10 µM), while it did not elicit a Ca2+ response by itself, potentiated the
increase in [Ca2+]i produced by OXA (17-33) (10 nM), when added at the same time as
OXA (17-33) (Figure 4). Pretreatment with BD1047 (50 µM, 30 min) or NE-100 (5 µM, 30
min), Sigma-1R antagonists, reduced the increase in [Ca2+]i produced by cocaine + OXA
(17-33) (10 nM), by 30.7% and 33.1%, respectively (Figure 4). This indicates that antagonism
of Sigma-1R abolished the potentiation produced by cocaine and further reduced the Ca2+
response to OXA (17-33) (10 nM) to the same level as in neurons treated with Sigma-1R
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antagonists before OXA (17-33) alone (Figure 4 vs. Figure 3). A comparison of the amplitude
of the [Ca2+]i increase in each condition is illustrated in Figure 4B (n = 6 neurons/condition).
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(middle), and BD1047 (50 µM) or NE-100 (5 µM), Sigma-1R antagonists (right). (B) Comparison of the amplitude of the 
increase in [Ca2+]i (average + SD) in each condition. Inhibition of PLD or antagonism of Sig-1R reduces the Ca2+ response 
elicited by OXA (17-33) (10 nM); p < 0.05 as compared to amplitude of [Ca2+]i increase produced by OXA (17-33) (*) or 
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Figure 4. Cocaine potentiates OXA (17-33)-induced increase in [Ca2+]i via Sigma-1R activation. (A) Illustration of average
Ca2+ responses (± SD) produced by application of cocaine (10 µM) alone (left, no response), cocaine (10 µM) and OXA
(17-33) (10 nM) (middle), and cocaine and OXA (17-33) in the presence of Sigma-1R antagonists BD1047 (50 µM) or NE-100
(5 µM) (right). (B) Comparison of the amplitude of the increase in [Ca2+]i (average + SD) in each condition. Cocaine
potentiates the Ca2+ response induced by OXA (17-33), while antagonism of Sigma-1R abolished the potentiation produced
by cocaine on the Ca2+ response elicited by OXA (17-33) (10 nM). * p < 0.05 (n = 6 neurons/condition).
A diagram summarizing the proposed mechanism of potentiation of orexin by cocaine
via Sigma-1R activation in nucleus accumbens neurons is illustrated in Figure 5.
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We next demonstrated that the OXA (17-33)-induced increase in [Ca2+]i was mediated 
by IP3-dependent Ca2+ release from ER, as previously reported [6]; the effect was abolished 
by IP3 receptor antagonists, but not affected by disruption of lysosomal Ca2+ stores. 
Figure 5. Diagram illustrating the proposed model of potentiation of orexin by cocaine via Sigma-1R in nucleus accumbens
neurons. (A) Orexin A acting on OX1 receptor activates PLC and PLD. PLC increases IP3 level and promotes the Ca2+ release
from endoplasmic reticulum via IP3 receptors (IP3R). PLD produces choline (from hydrolysis of phosphatidylcholine) that
acts on Sigma-1R to potentiate Ca2+ increase via IP3 R (higher increase in [Ca2+]i). (B) Inhibition of PLD or antagonism of
Sigma-1R limits the orexin A-OX1 receptor signaling to PLC-mediated IP3-dependent increase in Ca2+ (smaller increase
in [Ca2+]i). (C) Cocaine, via Sigma-1R activation, potentiates the PLC- and PLD-mediated increase in [Ca2+]i produced
by orexin A acting on OX1 (highest increase in [Ca2+]i). The diagram was created using the Motifolio Illustration Toolkit
Neuroscience (https://www.motifolio.com accessed on 7 March 2021).
3. Discussion
Orexin A, via activation of OX1 receptor, can activate both phospholipase C (PLC) and
phospholipase D (PLD) in various cell models [9,10] including neurons [37]. PLC activation
leads to hydrolysis of phosphoinositides and formation of inositol-1,4,5- trisphosphate (IP3),
the Ca2+-releasing second messenger that releases Ca2+ from endoplasmic reticulum (ER)
through IP3 receptors [38]. PLD activation promotes the hydr lysis of phosphatidylch line
to choline and phosphatidic acid [11]. Where s phosphatidic acid wa consi ered the
main ffector downstream to PLD activ tion, we recently identifi d choline as a second
messeng r that activates Sigm -1R [12].
Sigma-1 receptor is a chaperone protein expressed in the endoplasmic reticulum (ER),
mainly at the mitochondria-associated ER membrane domains (MAMs) [13]. Sigma-1Rs
interact with many different signaling proteins. At the ER, Sigma-1Rs potentiate the Ca2+
release via IP3 receptors [13]; they also interact with STIM1, the Ca2+ sensor for store-
operated Ca2+ entry [39]. Sigma-1R ligands include antidepressants, antipsychotics, and
drugs of abuse [40]. Cocaine, in addition to its canonical target that elevates synaptic
dopamine levels, binds to and activates Sigma-1Rs [41,42]. Neurons in the nucleus accum-
bens, a key area involved in the reward circuit [25], express Sigma-1R [27–29] and OX1
receptors [14,15]. Behavioral studies supported the cocaine–orexin interaction in nucleus
accumbens [3,22], but the underlying mechanisms remained unclear; this prompted us to
investigate the mechanisms of cocaine–orexin interaction at this level.
Orexin A has bee reported to incr ase cytosolic Ca2+ concentration, [Ca2+]i, in various
cells expressing orexi cep ors [1], including neurons [43]. W fi st tested the effect of
truncated orexin A peptide, OXA (17-33), a selective OX1 agonist [30], on [Ca2+]i in cultur d
nucleus accumbens n urons. (17-33) increased [Ca2+]i in a do e-dependent manner;
the effect was abolished by SB-334867 (1 µM), an OX1 antagonist [10,31] indicating that it
was mediated by OX1 receptors.
We next demonstrated that the OXA (17-33)-induced increase in [Ca2+]i was mediated
by IP3-dependent Ca2+ release from ER, as previously reported [6]; the effect was abolished
by IP3 receptor antagonists, but not affected by disruption of lysosomal Ca2+ stores.
In other series of experiments, pretreatment with PLD inhibitor reduced the Ca2+ re-
sponse elicited by OXA (17-33), supporting the involvement of PLD activation in addition
to PLC/IP3-dependent mechanisms in nucleus ambiguus neurons. This is in agreement
with previous studies reporting PLD-dependent mechanisms downstream to OX1 activa-
tion [9,10,37].
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In addition, antagonism of Sigma-1R reduced the Ca2+ response produced by OXA
(17-33), indicating for the first time the role of Sigma-1R in the response to OX1 activation
in the nucleus accumbens. The reduction in the response to OXA (17-33) produced by PLD
inhibition and Sigma-1R antagonism indicates that choline produced by PLD hydrolysis
of phosphatidylcholine, acting on Sigma-1R, as recently reported [12], potentiates the
IP3-mediated increase in [Ca2+]i.
Our results also indicate that cocaine, while it did not elicit a response by itself,
potentiated the increase in [Ca2+]i induced by OXA(17-33). This is similar to the potentiation
of orexin A-induced increase in [Ca2+]i by cocaine reported in VTA neurons [43]. In VTA
neurons, the effect of orexin and the potentiation by cocaine were abolished by suvorexant
(MK-4305), a dual orexin receptor OX1/OX2 antagonist [43,44]. Moreover, in nucleus
accumbens neurons, the potentiation of orexin response by cocaine was abolished by
Sigma-1R antagonists. Cocaine is a Sigma-1R agonist [26], and we previously reported that,
in nucleus accumbens neurons, cocaine via Sigma-1R potentiates the IP3-mediated increase
in [Ca2+]i [29]. Here, we identify an additional signaling mechanism for orexin A–OX1 via
choline-Sigma-1R and a critical role for Sigma-1R in the cocaine–orexin A interaction in
nucleus accumbens neurons.
4. Materials and Methods
4.1. Chemicals
OXA (17-33), i.e., truncated orexin A, a selective OX1 agonist [30], SB-334867, a
selective nonpeptide OX1 antagonist [31], and BD-1047 and NE-100 (Sigma-1 antagonists)
were obtained from Tocris (Bio-Techne Corporation, Minneapolis, MN, USA). VU0155056, a
PLD inhibitor [34], was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Cocaine
was supplied by the National Institute on Drug Abuse’s Drug Supply Program. All other
chemicals were from Sigma Aldrich (St. Louis, MO, USA), unless otherwise mentioned.
4.2. Neuronal Cell Culture
Nucleus accumbens neurons were dissociated from neonatal Sprague Dawley rats
(Ace Animal Inc., Boyertown, PA, USA) of both sexes as previously described [29,45].
Newborn rats were decapitated, and the brains quickly removed surgically and immersed
in ice-cold Hanks balanced salt solution (HBSS). The nucleus accumbens was identified,
removed, minced, and subjected to enzymatic (papain, 37 ◦C) and mechanical dissociation.
Cells were cultured in Neurobasal A medium (Life Technologies, ThermoFisher Scientific,
Carlsbad, CA, USA) containing 10% fetal bovine serum, 1% GlutaMax, and 1% penicillin–
streptomycin–amphotericin B solution at 37 ◦C in a humidified atmosphere with 5%
CO2.The mitotic inhibitor cytosine β-arabinofuranoside (1 µM) was added to the culture
to inhibit glial cell proliferation. For calcium imaging, neurons were cultured on round
25 mm diameter glass coverslips coated with poly-L-lysine, in six-well plates.
4.3. Measurement of Cytosolic Ca2+ Concentration
Cytosolic Ca2+ concentration, [Ca2+]i, was measured by calcium imaging methods
in nucleus accumbens neurons loaded with Fura-2AM, as previously described [29,45].
Cells were incubated with 5 µM Fura-2AM (Invitrogen) in HBSS at room temperature for
45 min, in the dark, and then incubated for another 45 min in HBSS to allow for complete
de-esterification of the dye. Coverslips (25 mm diameter) were subsequently mounted in
an open bath chamber (Warner Instruments, Hamden, CT, USA) on the stage of an inverted
microscope Nikon Eclipse TiE (Nikon Inc., Melville, NY, USA), equipped with a Perfect
Focus System and a Photometrics CoolSnap HQ2 CCD camera (Photometrics, Tucson,
AZ, USA). During the experiments, the Perfect Focus System was activated. Fura-2AM
fluorescence (emission = 510 nm), following alternate excitation at 340 and 380 nm, was
acquired at a frequency of 0.25 Hz. Images were acquired and analyzed using NIS-Elements
AR software (Nikon Inc.). After appropriate calibration with ionomycin and CaCl2 and
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with Ca2+ free and EGTA, respectively, the ratio of the fluorescence signals (340/380 nm)
was converted to Ca2+ concentrations [46].
4.4. Data Analysis
Data were expressed as the mean ± standard deviation (SD). Datasets were com-
pared for statistically significant differences using one-way ANOVA followed by post hoc
Bonferroni test. A p-value <0.05 was considered statistically significant.
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